PLSE · Pulse Biosciences, Inc · Stock research

Current Thesis

The timeline-compression leg described here in mid-August kept running, and what carried it in the week to 2026-08-21 was sell-side supply rather than new clinical data. Needham's Michael Matson initiated coverage on 2026-08-17 with a Buy and a $58 target — the first published target sitting above the market. Price closed at $50.42 on 2026-08-21 against a $44.54 close on 2026-08-14, clearing the prior 52-week high of $44.92 that had capped the post-Q2 advance. RSI(14) is 82.5 and the three-month price change is +94.7%.

The narrative being bought is unchanged from the 2026-08-06 Q2 disclosure: NANOPULSE-AF pivotal enrollment pulled to early October (roughly three months early, target raised to 164 patients), a CE-mark submission for the endocardial nsPFA catheter guided to H2 2026 with approval anticipated mid-2027, and a surgical NANOCLAMP CE filing targeted before end-2026. That converts a company previously modelled off a 2028 US launch into one with a European regulatory path a year earlier. The financial substrate under it is $434K of quarterly revenue, a GAAP net loss of $24.66M in Q2, $101.6M of cash at 2026-06-30 and a ~$20.5M quarterly non-GAAP cost run-rate.

The narrative is accelerating, dated by the 2026-08-17 Needham initiation (a fourth active covering firm) and the 2026-08-21 close at a new 52-week high. The qualifier matters: the marginal bid since 2026-08-15 has come from broker coverage expansion, not from a company datapoint, and no company-generated event is scheduled before enrollment completion guided to early October. A narrative advancing on distribution while the data calendar is empty is the late shape of accelerating.

Bullish and bearish views on Pulse Biosciences, Inc

The model's bull view on Pulse Biosciences, Inc (PLSE), in brief: Needham initiation, 2026-08-17: Buy, $58 target (Michael Matson). The bear view: Price sits above the published consensus. Both cases follow in full.

Bull Case

• Needham initiation, 2026-08-17: Buy, $58 target (Michael Matson). Fourth active covering firm; the only published target above the 2026-08-21 close of $50.42.
• Enrollment ahead of an already-accelerated guide. Q2 release (2026-08-06): past 82 evaluable patients across 12 active sites; target raised from 145 to 164 after a protocol amendment widening antiarrhythmic-drug eligibility; completion guided to early October, ~3 months early.
• European feasibility data is the strongest file item. From the 2026-08-06 call: 96% freedom from AF at one year on 24-hour Holter in the 5-second ablation cohort, 90% Kaplan-Meier freedom from recurrent arrhythmias at one year, 1.7% serious adverse event rate across 177 patients treated.
• A regulatory event now precedes the pivotal readout. Catheter CE submission guided H2 2026, approval anticipated mid-2027; NANOCLAMP CE filing targeted before end-2026. Before 2026-07-29 there was nothing dated between the 2027 endpoints and a 2028 launch.
• Insiders funded part of the raise. Of $46.8M net raised via ATM in Q2, ~$13M came from company insiders and $33.8M from outside investors (2026-08-06 release and call).
• Second indication on schedule. PRECISE-BTN expanded from 50 to 100 benign-nodule patients with enrollment near complete; the papillary thyroid microcarcinoma feasibility study was ~50% enrolled at Q2 with completion expected by year-end 2026.

Bear Case

• Price sits above the published consensus. stockanalysis.com's compilation on 2026-08-23 shows an average target of $41, 18.68% below the market, with Canaccord at $43 (raised from $32 on 2026-08-10), Mizuho $45 (2026-08-10) and Oppenheimer $35 (2026-07-28). Three of four targets are below the last close.
• An open $75M ATM with issuance already demonstrated. The equity distribution agreement was signed 2026-08-06 with Mizuho Securities USA as agent, on top of $46.8M net raised in Q2 and a further $10.7M net plus $1.8M of gross warrant proceeds after quarter-end. Shares can be sold in any session without pre-announcement.
• The October event is a process milestone, not efficacy. Enrollment completion says nothing about the primary endpoint; the 6- and 12-month reads land in 2027. The re-rating front-runs data by roughly a year.
• Revenue cannot beat. Q2 revenue was $434K against a $533.333K estimate — legacy product only. Every print is a cash, share-count and timeline update.
• Runway does not reach launch. Management framed at least five quarters from $101.6M at ~$20.5M/quarter (2026-08-06); that window ends before any anticipated approval converts to revenue.
• Competitive PFA is already commercial. Boston Scientific, Johnson & Johnson MedTech and Medtronic have pulsed-field platforms in market while Pulse is pre-approval on both sides of the Atlantic.

Setup & Price Structure

The 2026-08-21 close of $50.42 is the 52-week high — zero distance from it — after the $44.92 high that stood through mid-August was taken out in the week of the Needham initiation. That prior high is now the nearest structural shelf; a weekly close back under it would mean the initiation leg failed to hold new ground. The deeper reference is the pre-2026-07-29 regime, the $25.87–$28.68 range that preceded the enrollment-midpoint announcement; the post-Q2 advance is fully intact above roughly $36.

Crowding observables, stated as observables: RSI(14) at 82.5 on 2026-08-21; a three-month price change of +94.7%; price above three of the four published targets and 18.68% above the average per stockanalysis.com on 2026-08-23; an open $75M ATM signed 2026-08-06 whose sales agent, Mizuho, separately publishes a $45 target; Q2 ATM issuance of $46.8M net plus $10.7M net after quarter-end against 70.8M shares outstanding at 2026-06-30; No earnings date falls inside the next 30 days — Q3 is expected in early November — so there is no imminent print to compress positioning into.

Catalyst Calendar (next 30 days)

• Through 2026-09-22: no company-scheduled event. No investor conference appearance, data release or earnings date is on the calendar between 2026-08-23 and 2026-09-22. The nearest dated items sit beyond the window and are listed for completeness.
• ~2026-10-05 (est.) — NANOPULSE-AF pivotal enrollment completion (guided "early Q4" / early October).
• ~2026-11-05 (est.) — Q3 2026 results: share count after post-Q2 ATM sales, cash, cost run-rate, and a restatement of the 164-patient target and site count.
• 2026-12-31 — CE-mark submission for the endocardial nsPFA catheter (guided H2 2026).
• 2026-12-31 — CE filing for the NANOCLAMP surgical system (targeted before end-2026); completion of the papillary thyroid microcarcinoma feasibility study.

What Would Change Our Mind

The structure that has to hold is the breakout through the $44.92 shelf that was cleared in the week of the 2026-08-17 initiation. A weekly close below $44 puts price back inside the mid-August range and marks the initiation leg as a failed extension rather than a new base; a weekly close below $36 would unwind the entire post-Q2 advance and return price to the regime that existed before 2026-07-29.

On the fundamental side, the acceleration claim is what the whole re-rating rests on, and it is falsifiable on a date: no NANOPULSE-AF enrollment-completion announcement by 2026-10-31 removes the compression, since "early October" was management's own language on 2026-08-06. A further protocol amendment, a reduced enrollment target, or a lower site count at the Q3 print would do the same. On the European path, absence of a confirmed CE submission by 2026-12-31, or Q3 language pushing anticipated approval past mid-2027, pushes first revenue back toward the 2028 US frame. A financing structured outside the ATM — registered direct, convertible or a marketed follow-on — before enrollment completes would say the five-quarter runway framing was optimistic.

The read flips the other way if enrollment completion lands on time and the CE submission is confirmed in the same quarter, because that would put two regulatory-clock events ahead of the 2027 endpoint reads.

Correlation Notes

• Pulsed-field ablation complex. Read alongside Boston Scientific (Farapulse), Johnson & Johnson MedTech (Varipulse) and Medtronic (PulseSelect/Affera). Competitor 12-month freedom-from-AF data presented in larger patient sets at 2027 cardiology meetings is the direct comparator against the 90% Kaplan-Meier figure disclosed 2026-08-06.
• Pre-revenue medtech beta. With $434K of quarterly revenue and a beta of 1.65, the name trades on risk appetite for unprofitable small-cap healthcare rather than on fundamentals; drawdowns in that cohort transmit with amplification.
• Duggan-associated names. Majority holder Robert Duggan is also chairman and CEO of Summit Therapeutics; retail attention has historically moved across names carrying his ownership, which can add flow unrelated to Pulse's own newsflow.
• Financing-window sensitivity. With an open ATM, strength in the small-cap healthcare tape is itself a mechanism for share issuance, so the correlation runs both directions: a strong tape enables supply.